3-Mar-2025
Emergent BioSolutions Reports Strong 2024 Financial Turnaround
TipRanks (Mon, 3-Mar 10:56 PM ET)
Emergent BioSolutions tumbles 8% as Q4 revenue, 2025 guidance disappoints
Seeking Alpha News (Mon, 3-Mar 5:41 PM ET)
Emergent Biosolutions Non-GAAP EPS of $0.05 beats by $0.55, revenue of $194.7M misses by $59.97M
Seeking Alpha News (Mon, 3-Mar 5:05 PM ET)
Emergent BioSolutions Reports 2024 Financial Results
TipRanks (Mon, 3-Mar 4:51 PM ET)
Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results
Globe Newswire (Mon, 3-Mar 4:23 PM ET)
Here are the major earnings after the close today
Seeking Alpha News (Mon, 3-Mar 10:00 AM ET)
Emergent Biosolutions Q4 2024 Earnings Preview
Seeking Alpha News (Sun, 2-Mar 5:35 PM ET)
Earnings week ahead: TGT, COST, CRWD, AVGO, JD, PLUG, MRVL, and more
Seeking Alpha News (Sun, 2-Mar 8:00 AM ET)
WHO maintains public health emergency alert on mpox
Seeking Alpha News (Thu, 27-Feb 11:21 AM ET)
Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
Globe Newswire (Tue, 18-Feb 8:55 AM ET)
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
Emergent Biosolutions trades on the NYSE stock market under the symbol EBS.
As of March 3, 2025, EBS stock price declined to $6.83 with 1,387,046 million shares trading.
EBS has a beta of 4.55, meaning it tends to be more sensitive to market movements. EBS has a correlation of 0.18 to the broad based SPY ETF.
EBS has a market cap of $370.08 million. This is considered a Small Cap stock.
Last quarter Emergent Biosolutions reported $294 million in Revenue and $1.37 earnings per share. This fell short of revenue expectation by $-4 million and exceeded earnings estimates by $1.23.
In the last 3 years, EBS traded as high as $45.14 and as low as $1.42.
The top ETF exchange traded funds that EBS belongs to (by Net Assets): VTI, AVUV, XBI, VXF, PRFZ.
EBS has outperformed the market in the last year with a return of +113.4%, while the SPY ETF gained +16.7%. However, in the most recent history, EBS shares have underperformed the stock market with its stock returning -32.4% in the last 3 month period and -29.7% for the last 2 week period, while SPY has returned -2.2% and -4.3%, respectively.
EBS support price is $7.07 and resistance is $7.89 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EBS shares will trade within this expected range on the day.